Berinert denied as duplicate or overlapping therapy by Blue Cross Blue Shield?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Blue Cross Blue Shield typically requires
Blue Cross Blue Shield's specific coverage criteria for berinert are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Blue Cross Blue Shield angle on Berinert
## Why BlueCross BlueShield May Deny Berinert as "Duplicate Therapy"
Berinert is a plasma-derived C1 esterase inhibitor (C1-INH) concentrate used to treat acute attacks of hereditary angioedema (HAE). BCBS may issue a "duplicate therapy" denial when the member has a concurrent authorization or recent claim for another C1-INH product (such as Haegarda or Cinryze), a plasma kallikrein inhibitor (such as Kalbitor), or a bradykinin B2-receptor antagonist (such as Firazyr/icatibant) — reasoning that two on-demand or prophylactic HAE agents cannot both be medically necessary simultaneously. This denial is often appealable because the clinical rationale for having both an on-demand acute treatment and a prophylactic agent, or for transitioning between products, is well-recognized in HAE management and supported by specialty society guidance.
## Your Appeal Rights
Under ACA Section 2719 and ERISA Section 503, you have the right to a full-and-fair internal appeal and, if that is denied, independent external review through an accredited IRO. File the external-review request within four months of the final adverse determination. Given the acute nature of HAE attacks, expedited review (72-hour decision) is particularly important — severe attacks can be life-threatening, and delays in access to on-demand treatment constitute an urgent situation.
## The Appeal Process
1. Request the denial letter and the BCBS Medical/Coverage Policy for Berinert and the other HAE product(s) named in the duplicate-therapy determination. 2. Have the treating allergist, immunologist, or HAE specialist draft a letter distinguishing the clinical role of each agent. 3. File a Level 1 internal appeal with the documentation package. 4. If upheld, escalate to Level 2 and then external IRO review.
## Documentation to Gather
- Distinct clinical role documentation: A specialist letter explaining the different mechanisms of action and clinical roles of each agent (e.g., on-demand acute treatment vs. long-term prophylaxis, or the rationale for transitioning from one product to another during an overlap period).
- HAE diagnosis confirmation: Genetic or laboratory documentation of C1-INH deficiency or dysfunction confirming the HAE diagnosis, along with attack frequency and severity history.
- Treatment history and response: Records showing response — or lack of adequate response — to any other HAE agent previously tried, establishing why Berinert specifically is needed.
- Attack log or diary: A contemporaneous record of attack frequency, severity, and locations (particularly abdominal and laryngeal attacks) that establishes the clinical urgency.
- Prescriber medical-necessity letter: A detailed letter from the treating HAE specialist explaining why both agents (if applicable) serve distinct, non-duplicative clinical purposes, referencing the applicable US Hereditary Angioedema Association (HAEA) or HAE International guideline recommendation.
## Criteria-Mapping Structure
Address the "duplicate" characterization directly:
| BCBS Duplicate-Therapy Concern | Clinical Distinction / Chart Evidence | |---|---| | Other C1-INH or HAE agent on file | Different mechanism, route, or clinical role per specialist letter | | Overlap period coverage | Transition justification with start/stop dates and clinical rationale | | Prophylaxis vs. acute treatment distinction | Chart note distinguishing the two roles explicitly | | BCBS policy criterion for each agent | Separate criterion-by-criterion documentation for each |
A clear articulation of distinct clinical purpose — supported by specialist expertise and HAE society guidance — is the foundation of a successful duplicate-therapy appeal.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →Related appeal guides
- Blue Cross Blue Shield denied as duplicate or overlapping therapy of 17ohp Compounded
- Blue Cross Blue Shield denied as duplicate or overlapping therapy of AAT Augmentation
- Blue Cross Blue Shield denied as duplicate or overlapping therapy of Amphetamine Stimulant Prodrug
- Blue Cross Blue Shield denied as duplicate or overlapping therapy of Anti Cd 20 Ocrevus